dialed.bio [ CONTACT ]
SYS://RIBOSOME_COMPILER v2.0BOOTΔG: —

DE NOVO PEPTIDE BINDERS → PEPTIDE-DRUG CONJUGATES

Peptides
are Code.

Designed to Bind.

mRNA → PEPTIDEMSG_01
STEP_00TARGET: UNDISCLOSED · MODALITY: PDC · STATUS: DISCOVERY
01 / PLATFORM

Binders, compiled from scratch.

We treat a peptide like source code. AI models write new sequences against a target surface. We then score them, fold them in silico and test the best in the lab. No libraries to screen and no natural scaffolds to borrow.

> 01_GENERATE

Generative models propose de novo peptide binders shaped to a chosen epitope.

> 02_FILTER

Structure prediction and physics-based scoring cut thousands of designs down to a short list.

> 03_VALIDATE

Tight design–build–test loops measure binding and feed every result back into the model.

02 / PIPELINE

Pipeline.

IDMODALITYINDICATIONSTAGE
DLD-001First-in-class peptide-drug conjugateSolid tumorsDISCOVERY
DLD-002UndisclosedUndisclosedRESEARCH

// Target undisclosed.

03 / WHY PDCs

Designed to Target.

  • SIZE A peptide is a fraction of an antibody's size, so it can get deeper into dense solid tumors.
  • SPEED Fast clearance from healthy tissue can widen the window between efficacy and toxicity.
  • PRECISION A defined, synthetic molecule gives exact control over linker and payload placement.
  • ITERATION Chemical synthesis keeps design cycles in weeks, not months.
04 / CONTACT

Let's talk.

Investors, partners and scientists: write to us.

hello@dialed.bio →